Cohort 3: These Japanese Red Cedar atopic subjects will receive intradermal (ID) injections of the same CryJ2-DNA-LAMP vaccine previously used in Phase IA and IB studies. Cohort #3 will receive four (4) 1.08 mg doses at 14 day intervals. Each 1.08 mg dose will require administration of two (2) separate 0.200 ml volumes of a 2.7 mg/ml vaccine concentrate using the needle-free Biojector device. Each of the four volumes will be injected at different sites on the same or different deltoid muscle.